论文部分内容阅读
目的观察优福宁、胸腺肽联合抗结核药治疗耐多药结核病的近期效果。方法将62例耐多药结核病患者随机分为观察组(31例)和对照组(31例)。对照组采用抗结核治疗,观察组在此基础上加用胸腺肽α1 1.6mg,皮下注射,一周两次;优福宁每次4粒,每天3次。疗程6个月。结果观察组6个月痰菌阴转率(77.42%)、病灶吸收好转率(58.07%)均显著高于对照组(P均<0.05)。但安全性分析及不良反应发生率两组比较差异无显著性。结论优福宁、胸腺肽联合抗结核药治疗耐多药结核病效果满意。
Objective To observe the short-term effects of Youfu Ning and thymosin combined with anti-tuberculosis drugs in the treatment of multidrug-resistant tuberculosis. Methods Sixty-two MDR-TB patients were randomly divided into observation group (31 cases) and control group (31 cases). In the control group, anti-TB treatment was used. In the observation group, thymosin α1 1.6mg was injected subcutaneously twice a week for 4 weeks. Course of 6 months. Results The sputum negative conversion rate (77.42%) and the improvement rate of focal absorption (58.07%) in the observation group for 6 months were significantly higher than those in the control group (all P <0.05). However, the safety analysis and the incidence of adverse reactions were no significant difference between the two groups. Conclusion Youfu Ning, thymosin combined with anti-TB drug treatment of MDR-TB results are satisfactory.